Trinity Biotech (NASDAQ:TRIB) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a research report report published on Wednesday. The brokerage issued a hold rating on the stock.

Trinity Biotech Stock Down 2.9 %

NASDAQ:TRIB opened at $1.32 on Wednesday. Trinity Biotech has a fifty-two week low of $0.74 and a fifty-two week high of $3.55. The firm’s fifty day simple moving average is $0.93 and its 200-day simple moving average is $1.61.

Institutional Investors Weigh In On Trinity Biotech

A hedge fund recently raised its stake in Trinity Biotech stock. Hunter Associates Investment Management LLC increased its position in shares of Trinity Biotech plc (NASDAQ:TRIB) by 5.2% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 378,590 shares of the company’s stock after purchasing an additional 18,780 shares during the quarter. Hunter Associates Investment Management LLC’s holdings in Trinity Biotech were worth $334,000 as of its most recent filing with the SEC. 78.97% of the stock is currently owned by hedge funds and other institutional investors.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.